Immutep Limited IMMP
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- +8.74%
- 1 year
- +84.02%
- Market cap
- 22.92M
- Revenue (ttm)
- 3.84M
- EPS (ttm)
- -7.30
- Shares out
- 145.46M
- Forward P/E
- -7.33
- YTD return
- +8.74%
- 1-year return
- +84.02%
- 50-day average
- 2.00
- 200-day average
- 2.32
- Volume
- 44.78K
- Avg volume
- 25.45K
- Open
- 3.41
- Previous close
- 3.42
- Day's range
- 3.09 – 3.41
- 52-week range
- 2.66 – 70.60
- Beta
- 1.92
- Analysts
- Strong Buy
- Price target
- 9.50 (+205.5%)
Key statistics
- Enterprise value
- 2.77B
- Price / sales
- 76.53
- Price / book
- 15.23
- Revenue growth
- -4.90%
- Free cash flow
- -23.25M
- Total cash
- 181.88M
- Total debt
- 1.59M
- Return on equity
- -26.21%
- Short % of float
- 3.56%
Fundamental scorecard
8 of 25 checks passed on IMMP’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 5, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Sep 7, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| Sep 2, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Aug 27, 2019 | Jun 1, 2019 | 0.00 | — | — | — |
| Sep 4, 2018 | Jun 1, 2018 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Baird | main | Outperform | Outperform |
| Jun 27, 2024 | Baird | main | Outperform | Outperform |
| May 17, 2024 | Capital One | init | — | Overweight |
| Aug 28, 2023 | Baird | reit | Outperform | Outperform |
| Aug 3, 2023 | Baird | init | — | Outperform |
| Aug 2, 2023 | Baird | init | — | Outperform |
About Immutep Limited
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- immutep.com
News
Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial
Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial Reported Earlier, Immutep Says Soft Tissue Sarcoma Patients With Post-Treatment TIL Above 310 Cells/mm² Had 95.0% 12-Month Disease-Free Survival Versus 64.9%; Overall DFS At 81.1% In EFTISARC-NEO
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep Reports Encouraging EFTISARC-NEO Phase II Sarcoma Survival Data; Efti + KEYTRUDA + Radiotherapy Shows 81.1% 12-Month DFS, 94.1% LRFS And 86.2% DMFS In 38 Patients
Immutep Refocuses Efti Development On HNSCC, Soft Tissue Sarcoma; New Trial Starts Targeted For H2 2027
Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program
Immutep Presents ePoster At European Society For Medical Oncology Congress 2026 For Its Eftilagimod Alfa In Combination With KEYTRUDA
Your note
Sign in to keep a note on IMMP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 0.62% | 908,141 | 1.80M | Sep 29, 2024 |
| Meridian Wealth Management, LLC | 0.27% | 398,450 | 788.93K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.08% | 112,503 | 222.75K | Sep 29, 2024 |
| XY Capital Ltd | 0.07% | 108,349 | 214.53K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.06% | 80,489 | 159.37K | Sep 29, 2024 |
| Pfg Investments, LLC | 0.04% | 51,000 | 100.98K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Biotechnology ETF | 0.60% | 875,877 | 1.73M | Oct 30, 2024 |
| Trust for Professional Managers-ActivePassive International Equity ETF | 0.08% | 117,969 | 233.58K | Aug 30, 2024 |
| Brighthouse Fds Tr II-BH/Dimensional International Small Co Port | 0.01% | 8,886 | 17.59K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 18,722 | 37.07K | Oct 30, 2024 |
| DFA Asia Pacific Small Company Series | 0.00% | 7,245 | 14.35K | Jul 30, 2024 |
| DFA International Sustainability Core 1 Portfolio | 0.00% | 4,300 | 8.51K | Jul 30, 2024 |
